Tango Therapeutics (TNGX) Projected to Post Quarterly Earnings on Thursday

Tango Therapeutics (NASDAQ:TNGX) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Tango Therapeutics to post earnings of ($0.31) per share and revenue of $0.5560 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics Trading Up 1.2%

Tango Therapeutics stock opened at $12.88 on Wednesday. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $13.60. The company has a fifty day simple moving average of $11.16 and a 200 day simple moving average of $9.13. The company has a market cap of $1.73 billion, a P/E ratio of -13.85 and a beta of 1.75.

Insiders Place Their Bets

In other news, CFO Daniella Beckman sold 10,317 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. This trade represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the sale, the director owned 1,629,254 shares of the company’s stock, valued at approximately $19,974,654.04. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 59,288 shares of company stock worth $726,871 in the last quarter. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TNGX. XTX Topco Ltd bought a new stake in Tango Therapeutics during the fourth quarter worth about $335,000. VARCOV Co. bought a new stake in shares of Tango Therapeutics during the 4th quarter worth approximately $261,000. Virtus Investment Advisers LLC increased its stake in Tango Therapeutics by 26.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock valued at $252,000 after acquiring an additional 5,920 shares during the last quarter. Tudor Investment Corp ET AL raised its position in Tango Therapeutics by 27.4% during the fourth quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock valued at $605,000 after purchasing an additional 14,679 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Tango Therapeutics during the fourth quarter valued at approximately $4,825,000. Institutional investors own 78.99% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price objective for the company. Wolfe Research initiated coverage on Tango Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Mizuho started coverage on Tango Therapeutics in a research report on Monday. They set an “outperform” rating and a $19.00 price target on the stock. Wall Street Zen upgraded Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Finally, Piper Sandler raised their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.